In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche's End Run Into the Cervical Cancer Screening Market

Executive Summary

The announcement of a merger between Digene, the maker of the only FDA-approved test for HPV, and Cytyc disappointed diagnostics giant Roche, Digene's European distributor. Roche had also contemplated a more strategic relationship with Digene. But it had a back-up plan. In June, it bought Institut Pasteur's HPV IP portfolio, which includes rights to some of Digene's markers. Now, Roche will go head to head with Digene in what may be one of the first significant battles between two molecular diagnostics platforms.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts